IL155992A0 - Pharmaceutical compositions for the oral delivery of pharmacologically active agents - Google Patents

Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Info

Publication number
IL155992A0
IL155992A0 IL15599201A IL15599201A IL155992A0 IL 155992 A0 IL155992 A0 IL 155992A0 IL 15599201 A IL15599201 A IL 15599201A IL 15599201 A IL15599201 A IL 15599201A IL 155992 A0 IL155992 A0 IL 155992A0
Authority
IL
Israel
Prior art keywords
pharmacologically active
active agents
pharmaceutical compositions
oral delivery
delivery
Prior art date
Application number
IL15599201A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL155992A0 publication Critical patent/IL155992A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15599201A 2000-12-06 2001-12-05 Pharmaceutical compositions for the oral delivery of pharmacologically active agents IL155992A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25172900P 2000-12-06 2000-12-06
PCT/EP2001/014294 WO2002045754A2 (en) 2000-12-06 2001-12-05 Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Publications (1)

Publication Number Publication Date
IL155992A0 true IL155992A0 (en) 2003-12-23

Family

ID=22953160

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15599201A IL155992A0 (en) 2000-12-06 2001-12-05 Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IL155992A IL155992A (en) 2000-12-06 2003-05-19 Pharmacological preparations of pharmacologically active substances for oral administration

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155992A IL155992A (en) 2000-12-06 2003-05-19 Pharmacological preparations of pharmacologically active substances for oral administration

Country Status (27)

Country Link
US (1) US7049283B2 (xx)
EP (1) EP1341526B1 (xx)
JP (2) JP4898078B2 (xx)
KR (1) KR100847695B1 (xx)
CN (1) CN1304048C (xx)
AT (1) ATE513541T1 (xx)
AU (2) AU3454702A (xx)
BR (2) BR0115965A (xx)
CA (1) CA2436599C (xx)
CY (1) CY1112562T1 (xx)
CZ (1) CZ305418B6 (xx)
DK (1) DK1341526T3 (xx)
EC (1) ECSP034639A (xx)
ES (1) ES2367009T3 (xx)
HK (1) HK1059565A1 (xx)
HU (1) HU230632B1 (xx)
IL (2) IL155992A0 (xx)
MX (1) MXPA03005096A (xx)
NO (1) NO332936B1 (xx)
NZ (1) NZ526196A (xx)
PL (1) PL209703B1 (xx)
PT (1) PT1341526E (xx)
RU (1) RU2287999C2 (xx)
SI (1) SI1341526T1 (xx)
SK (1) SK287613B6 (xx)
WO (1) WO2002045754A2 (xx)
ZA (1) ZA200304295B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4588221B2 (ja) * 1999-04-05 2010-11-24 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物
AU2002344371B2 (en) * 2001-06-01 2006-06-29 Novartis Ag Orally administering parathyroid hormone and calcitonin
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
TWI307279B (en) * 2002-08-01 2009-03-11 Novartis Ag Oral administration of calcitonin
NZ542852A (en) * 2003-03-17 2008-09-26 Japan Tobacco Inc Pharmaceutical compositions of CETP inhibitors
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CA2529604C (en) * 2003-07-11 2012-05-08 Novartis Ag Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
DK3260117T3 (da) * 2003-09-12 2019-07-01 Amgen Inc Hurtigt opløsende formulering, der omfatter cinacalcet-hcl
EP1750721A4 (en) * 2004-05-19 2012-10-31 Emisphere Tech Inc TOPICAL FORMULATIONS BASED ON CROMOGLYCIC ACID
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0427603D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
EP1843755B1 (en) * 2005-02-01 2015-04-01 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
WO2007005995A2 (en) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
CN101627011A (zh) 2005-09-19 2010-01-13 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
AU2006318815B2 (en) 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition
CA2642761A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
WO2008021088A2 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
CN103356997A (zh) * 2006-08-31 2013-10-23 诺瓦提斯公司 用于口服递送的包含hgh 的药物组合物
CA2572004A1 (en) * 2006-12-08 2008-06-08 Bernard Charles Sherman Tablets comprising entacapone and crospovidone
WO2008109385A2 (en) * 2007-03-02 2008-09-12 Novartis Ag Oral administration of a calcitonin
WO2009059188A1 (en) 2007-11-02 2009-05-07 Emisphere Technologies, Inc. Method of treating vitamin b12 deficiency
WO2010020978A1 (en) 2008-08-18 2010-02-25 Oramed Pharmaceuticals Ltd Methods and compositions for oral administration of proteins
MX2011009559A (es) * 2009-03-12 2012-01-12 Nordic Bioscience As Tratamiento de la diabetes y el sindrome metabolico.
CN103025327A (zh) * 2010-06-09 2013-04-03 艾米斯菲尔技术公司 口服缺铁疗法
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
MX355361B (es) 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
SI2827845T1 (sl) 2012-03-22 2019-04-30 Novo Nordisk A/S Sestavki, ki obsegajo dostavno sredstvo in njihova priprava
RU2641198C3 (ru) 2012-03-22 2021-12-10 Ново Нордиск А/С Композиции glp-1 пептидов и их получение
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
NZ735250A (en) * 2015-07-08 2020-08-28 Research & Business Found Sungkyunkwan Univ Pyrrolidine carboxamido derivatives and methods for preparing and using the same
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
CN107080739A (zh) * 2017-04-17 2017-08-22 深圳市泛谷药业股份有限公司 一种用于口服给药的固体快速释放布南色林片及其制备方法
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
JP2021054781A (ja) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド 共結晶形エフィナコナゾール、及びその製造方法
KR102301743B1 (ko) * 2020-12-29 2021-09-13 대봉엘에스 주식회사 에피나코나졸 경구용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015633A (en) 1987-04-27 1991-05-14 E. R. Squibb & Sons, Inc. Method for inhibiting loss of cognitive functions employing an ace inhibitor
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5002771A (en) 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
IT1238072B (it) 1990-01-19 1993-07-03 Sclavo Spa Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
JPH052771A (ja) * 1991-06-25 1993-01-08 Pioneer Electron Corp 光記録媒体
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
AU4353996A (en) 1994-12-14 1996-07-03 Bioglan Ireland (R & D) Limited Pharmaceutical tablet formulations for direct compression
CN1151836C (zh) * 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1093819B1 (en) 1997-02-07 2006-05-03 Emisphere Technologies, Inc. Compound and composition for delivering active agents
NZ506289A (en) 1998-03-16 2004-12-24 Nektar Therapeutics Aerosolized active agent delivery to the lungs at a flow rate of less than 17 liters per minute
AU3574500A (en) 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
WO2000059480A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making
JP4588221B2 (ja) 1999-04-05 2010-11-24 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物

Also Published As

Publication number Publication date
KR20040018309A (ko) 2004-03-03
AU3454702A (en) 2002-06-18
HUP0302319A2 (hu) 2003-11-28
CA2436599C (en) 2011-01-25
SK287613B6 (sk) 2011-04-05
AU2002234547B2 (en) 2005-03-24
JP2004515480A (ja) 2004-05-27
ZA200304295B (en) 2004-05-10
DK1341526T3 (da) 2011-10-03
RU2287999C2 (ru) 2006-11-27
ATE513541T1 (de) 2011-07-15
WO2002045754A2 (en) 2002-06-13
BR0115965A (pt) 2003-10-28
HUP0302319A3 (en) 2013-04-29
US7049283B2 (en) 2006-05-23
MXPA03005096A (es) 2003-09-05
JP2009185052A (ja) 2009-08-20
NO20032511L (no) 2003-06-03
CN1479612A (zh) 2004-03-03
ES2367009T3 (es) 2011-10-27
IL155992A (en) 2008-04-13
NO20032511D0 (no) 2003-06-03
HU230632B1 (hu) 2017-05-29
PL209703B1 (pl) 2011-10-31
SK6882003A3 (en) 2004-01-08
ECSP034639A (es) 2003-07-25
PT1341526E (pt) 2011-09-01
BRPI0115965B1 (pt) 2017-09-26
CY1112562T1 (el) 2016-02-10
CN1304048C (zh) 2007-03-14
HK1059565A1 (en) 2004-07-09
KR100847695B1 (ko) 2008-07-23
NO332936B1 (no) 2013-02-04
EP1341526B1 (en) 2011-06-22
CA2436599A1 (en) 2002-06-13
WO2002045754A3 (en) 2003-01-03
CZ20031566A3 (cs) 2003-09-17
SI1341526T1 (sl) 2011-10-28
US20020123459A1 (en) 2002-09-05
EP1341526A2 (en) 2003-09-10
NZ526196A (en) 2005-01-28
PL362247A1 (en) 2004-10-18
CZ305418B6 (cs) 2015-09-09
JP4898078B2 (ja) 2012-03-14

Similar Documents

Publication Publication Date Title
AU3454702A (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents
HK1089950A1 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
ITMI20001173A0 (it) Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva.
PL348734A1 (en) New sustained release oral formulations
IL166561A0 (en) Pharmaceutical compositions
GEP20074047B (en) Pramipexole once-daily dosage form
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
MY118151A (en) Pharmaceutical formulations containing voriconazole.
EP1392241A4 (en) SYSTEM FOR THE OSMOTIC RELEASE OF PHARMACEUTIC EFFECTIVENESS
NZ527157A (en) Compositions for delivering bisphosphonates
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
IS6263A (is) Lyfjasamsetningar, sem innihalda trípeptíð
MXPA03010761A (es) Combinaciones farmaceuticas.
IL151909A0 (en) Peptide conjugates for drug delivery
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
EP1379508A4 (en) N- (ARYL) -2-ARYLETHESULFONAMIDES AND THEIR THERAPEUTIC APPLICATIONS
WO2003041656A3 (en) Soluble drug extended release system
HUP0303860A3 (en) A pharmaceutical tablet having a high active ingredient
MY128759A (en) Oral controlled release formulations
MY136370A (en) Oxazolidinone tablet formulation
MXPA01008348A (es) Microcapsulas para la liberacion prolongada de farmacos.
AU5654701A (en) Drug delivery mask
DE69904020D1 (de) Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed